This suggests that transcriptional subtyping and IDH mutational status do not fully describe resistance to radiation, in line with the concept that additional markers may be necessary to better predict the clinical outcomes of glioma (Sturm et al, 2012; Wang et al, 2017, 2021b; Behnan et al, 2019). The gene discussed is IDH2; the disease is central nervous system cancer.